20 Elements of Postmarket Reporting Building Periodic Benefit-Risk Evaluation Reports
Drugmakers are required to conduct postmarket surveillance activities showing that their products continue to be safe and effective. But the types — formats — and frequency — of the reports mandated can vary.
The final ICH guidance adopted by the FDA in July 2016 lays out the requirements for postmarket surveillance reporting in international markets.
This FDAnews Brief outlines the new guidance, providing detailed information on what each of the 20 modules should contain and how to conduct benefit-risk analysis. It also explains how certain modules can be adapted to meet other regulatory requirements, including ICH’s drug development safety guideline, ICH E2F, and FDA adverse event reporting regulations.
With the 20 Elements of Postmarket Reporting brief you will learn how to prepare Periodic Benefit-Risk Evaluation Reports (PBRER) in a modular format that can be used in other postmarket surveillance reports required by the FDA and international regulators. The 20 modules are:
Worldwide Marketing Approval Status
Actions Taken in the Reporting Interval for Safety Reasons
Changes to Reference Safety Information
Estimated Exposure and Use Patterns 5.1 Cumulative Subject Exposure in Clinical Trials
Data in Summary Tabulations
Summaries of Significant Findings from Clinical Trials during the Reporting Period
Findings From Non-Interventional Studies
Information From Other Clinical Trials and Sources
Other Periodic Reports
Lack of Efficacy in Controlled Clinical Trials
Overview of Signals: New, Ongoing, or Closed
Signal and Risk Evaluation
Integrated Benefit-Risk Analysis for Approved Indications
Conclusions and Actions
You will learn:
How PBRERs differ from the previously required Periodic Safety Update Reports
How to incorporate core data sheets into PBRERs
The importance of International Birth Dates and Data Lock Points
How to coordinate the frequency of individual postmarket reports required by various regulatory agencies
Which elements of a PBRER can be used in other postmarket reports
Differing interpretations of the words “efficacy” and “effectiveness”
The meaning of the terms “key risk” and “key benefit”
Use this 20-element plan to ensure you conduct postmarket surveillance activities that show that your products are safe and effective.
Order Your Copy Today
PDF Edition — $177
Who Will Benefit
Research and development
Postmarket surveillance staff
Save money with a license agreement allowing significant numbers of users access to an electronic version of this book. For multi-user access to multiple titles, FDAnews offers the FDAnews Online Library — a personalized collection of FDAnews publications that is fully searchable. Contact Customer Service for a quote or more information.
Not satisfied with your publication? For the PDF version, you must notify FDAnews within 24 hours of receipt of purchase and we will refund 100 percent of your purchase price.